International Stem Cell Corporation (ISCO) Continu
Post# of 124
Posted On: 02/02/2016 6:42:14 PM
International Stem Cell Corporation (ISCO) Continues Upward Climb toward Changing the Face of Regenerative Medicine
A California-based biotechnology company, International Stem Cell Corporation (OTCQB: ISCO) focuses its energies on developing restorative medicine using stem cell technology. Its innovative parthenogenesis technology uses human stem cells derived from unfertilized oocytes (eggs), which helps the company avoid any ethical issues involving the destruction of viable human embryos. ISCO also produces and markets cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology. For even more revenue, the company’s other subsidiary, Lifeline Skin Care, markets and sells a skin care line that promises rejuvenation and beauty.
In December, Lifeline Skin Care launched its Molecular Renewal Serum™, just in time for the holidays. This product contains an impressive nano-compound that works with skin to replenish elasticity and smoothness. During testing, the serum showed improvement in skin’s resilience and a decrease in roughness without any negative side effects. The serum also stimulates collagen production, which lends strength to skin by regrowing dead skin cells.
That same month, ISCO announced that it had entered a master clinical research agreement with Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement cleared the way for scientists to conduct a Phase I/IIa clinical trial studying the effects of human parthenogenetic stem cells in people with Parkinson’s disease. Patients are to be enrolled during the first quarter of 2016.
ISCO’s groundbreaking stem cells are created by stimulating oocytes into dividing themselves into histocompatible cells. The company strives to create immune matching cells, so that people do not reject the treatment. So far, ISCO scientists have developed the first line of stem cells that can be used as therapeutic cells for millions of people with minimal rejection. The company also aligns itself with the UniStemCell Bank, the first collection of non-embryonic stem cells, in the hopes of increasing widespread use and scientific breakthroughs.
With the steady financial growth of ISCO and its subsidiaries, the company hopes to continue making great strides in regenerative techniques for eye, liver, and nervous system diseases.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
A California-based biotechnology company, International Stem Cell Corporation (OTCQB: ISCO) focuses its energies on developing restorative medicine using stem cell technology. Its innovative parthenogenesis technology uses human stem cells derived from unfertilized oocytes (eggs), which helps the company avoid any ethical issues involving the destruction of viable human embryos. ISCO also produces and markets cells and growth media for therapeutic research worldwide through its subsidiary, Lifeline Cell Technology. For even more revenue, the company’s other subsidiary, Lifeline Skin Care, markets and sells a skin care line that promises rejuvenation and beauty.
In December, Lifeline Skin Care launched its Molecular Renewal Serum™, just in time for the holidays. This product contains an impressive nano-compound that works with skin to replenish elasticity and smoothness. During testing, the serum showed improvement in skin’s resilience and a decrease in roughness without any negative side effects. The serum also stimulates collagen production, which lends strength to skin by regrowing dead skin cells.
That same month, ISCO announced that it had entered a master clinical research agreement with Florey Institute of Neuroscience and Mental Health, one of the world’s leading brain research centers. The agreement cleared the way for scientists to conduct a Phase I/IIa clinical trial studying the effects of human parthenogenetic stem cells in people with Parkinson’s disease. Patients are to be enrolled during the first quarter of 2016.
ISCO’s groundbreaking stem cells are created by stimulating oocytes into dividing themselves into histocompatible cells. The company strives to create immune matching cells, so that people do not reject the treatment. So far, ISCO scientists have developed the first line of stem cells that can be used as therapeutic cells for millions of people with minimal rejection. The company also aligns itself with the UniStemCell Bank, the first collection of non-embryonic stem cells, in the hopes of increasing widespread use and scientific breakthroughs.
With the steady financial growth of ISCO and its subsidiaries, the company hopes to continue making great strides in regenerative techniques for eye, liver, and nervous system diseases.
For more information, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
(0)
(0)